Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_2
1
33%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(2)

Detailed Status

Withdrawn1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
N/A1 (33.3%)

Trials by Status

withdrawn133%
terminated133%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_3

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

NCT05717166
withdrawnphase_2

ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer

NCT05245760
terminatednot_applicable

Image-Based Quantitative Assessment of Acute Radiation-Induced Changes in Glioma

NCT03168919

Clinical Trials (3)

Showing 3 of 3 trials
NCT05717166Phase 3

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

Recruiting
NCT05245760Phase 2

ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer

Withdrawn
NCT03168919Not Applicable

Image-Based Quantitative Assessment of Acute Radiation-Induced Changes in Glioma

Terminated

All 3 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
3